Efficacy and Safety of the Investigational Device, SurgiShield Anti-Adhesion Barrier Gel
The Aim of This Study is to Evaluate the Efficacy and Safety of the Investigational Device, SurgiShield Anti-Adhesion Barrier Gel Made by D Med
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
ChoongChungBukDo
-
ChungJu, ChoongChungBukDo, Korea, Republic of
- Chungbook National University Hospital
-
-
Chungcheongnam-do
-
Cheonan, Chungcheongnam-do, Korea, Republic of, 31116
- Dankook University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- older than 21 years of age
- both side sinusitis
- will undergo endoscopic sinus surgery
- volunteers with informed consent and signature
Exclusion Criteria:
- suppressed immunity patient
- systemic grave condition
- pregnant
- cancer
- severe disease patients
- asthma patients
- AIDS
- cystic fibrosis
- ciliary immobility syndrome
- neutropenia neutrophil
- immunoglobulin deficiency
- wound healing immune disease
- severe liver disease
- severe kidney disease
- lymph or blood clotting disorder or patients treated with coagulants
- patients taking oral or parenteral glucose for diabetes thrombocytopenia
- infectious disease
- currently lactating
- severe septal deviation
- case where there is a severe difference in sinusitis state between sides of nose: there is a 3 or more score difference on the Lund-Mackey CT scan scoring system PNS(ParaNasalSinus)
- shellfish allergy
- food allergy
- had endoscopic sinus surgery in the past
- patient with large sinus polyps
- patients who have received treatment for extrasinus complication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Active / control
One side has been treated with SurgiShield
|
in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site merocel in the inflated state maintained for 36~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site |
|
No Intervention: No intervention
One side has no intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adhesion Rate
Time Frame: at 2 weeks
|
Adhesion rate at 2 weeks after ESS(endoscopic sinus surgery)
|
at 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adhesion Rate
Time Frame: at 1 and 4 weeks
|
Adhesion rate at 1 and 4 weeks after ESS(endoscopic sinus surgery) Bleeding score at 0,2,4,6,8,10 minutes after ESS
|
at 1 and 4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DMED-SS001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.